imatinib treatment reduces brain injury in a murine model of traumatic brain injury

Clicks: 308
ID: 206953
2015
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #75 of 395 articles by views in macromolecular bioscience

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 395 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Current therapies for Traumatic brain injury (TBI) focus on stabilizing individuals and on preventing further damage from the secondary consequences of TBI. A major complication of TBI is cerebral edema, which can be caused by the loss of blood brain barrier (BBB) integrity. Recent studies in several CNS pathologies have shown that activation of latent platelet derived growth factor-CC (PDGF-CC) within the brain can promote BBB permeability through PDGF receptor α (PDGFRα) signaling, and that blocking this pathway improves outcomes. In this study we examine the efficacy for the treatment of TBI of an FDA approved antagonist of the PDGFRα, Imatinib. Using a murine model we show that Imatinib treatment, begun 45 minutes after TBI and given twice daily for 5 days, significantly reduces BBB dysfunction. This is associated with significantly reduced lesion size 24 hours, 7 days, and 21 days after TBI, reduced cerebral edema, determined from apparent diffusion co-efficient (ADC) measurements, and with the preservation of cognitive function. Finally, analysis of CSF from human TBI patients suggests a possible correlation between high PDGF-CC levels and increased injury severity. Thus, our data suggests a novel strategy for the treatment of TBI with an existing FDA approved antagonist of the PDGFRα.
Reference Key
su2015frontiersimatinib Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Enming Joe Su;Linda eFredriksson;Linda eFredriksson;Mia eKanzawa;Shannon eMoore;Erika eFolestad;Tamara K Stevenson;Ingrid eNilsson;Maithili eSashindranath;Gerald P Schielke;Mark eWarnock;Margaret eRagsdale;Kris eMann;Anna-Lisa E Lawrence;Robert Lindsay Medcalf;Ulf eEriksson;Geoffrey G Murphy;Geoffrey G Murphy;Daniel A Lawrence;Daniel A Lawrence
Journal macromolecular bioscience
Year 2015
DOI
10.3389/fncel.2015.00385
URL
http://journal.frontiersin.org/Journal/10.3389/fncel.2015.00385/full
Keywords
Traumatic brain injury imatinib blood brain barrier morris water maze cerebral edema neuropsychiatry biological psychiatry tbi outcomeneurosciences

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.